Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chuikyo Members Frown on Zolgensma’s Sakigake Premium; Topic Up for 2022 Pricing Debate
Japan’s key reimbursement policy panel has given the nod to the listing of Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec), but its members were not happy about the sakigake premium granted despite its delayed approval primarily blamed…
To read the full story
Related Article
- Zolgensma Hits Japan Market with Stringent Conditions Attached
May 21, 2020
- Hodanren Criticizes Zolgensma’s High NHI Price as “Result of a Money Game”
May 18, 2020
- Japan Regulators Upped Zolgensma Price after Novartis Complaints: Chuikyo Paper
May 13, 2020
- Zolgensma to Get Japan’s Highest List Price 167 Million Yen, but Peak Sales Put at Just 4 Billion Yen
May 12, 2020
- Novartis Offers Free Access Program for Zolgensma Diagnostic
May 11, 2020
- Novartis’ Flawed and Delayed Inquiry Responses in Zolgensma Review “Extremely Unusual”: PMDA Report
April 16, 2020
- Novartis Japan Chided over Flawed Zolgensma Data, Delayed Responses
April 8, 2020
- Drug Pricing Rules to Be Applied to Zolgensma: Chuikyo
March 25, 2020
- (Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually
March 19, 2020
REGULATORY
- Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs
January 30, 2026
- MHLW to Ease Uniform Driving Restrictions on Oral Antiepileptics
January 29, 2026
- MHLW Eyes Distribution Rules in Revamped Supply Support Premium: Chuikyo
January 29, 2026
- Entyvio, Rexulti, and Lenvima among 15 More Drugs Picked for IRA Price Talks
January 29, 2026
- Japan’s Lower House Campaign Begins amid Fragmented Political Set-Up
January 28, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…